All In Biotech

Drug Trial Radar · NCT04629729

FT819 in Subjects With B-cell Malignancies

A Phase I Study of FT819 in Subjects With B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

54

Actual

Start

Jul 12, 2021

Primary completion

Jun 18, 2025

Study completion Sep 30, 2039

Sponsor

Lead sponsor
Fate TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Conditions

  • Lymphoma, B-Cell
  • Chronic Lymphocytic Leukemia
  • Precursor B-Cell Acute Lymphoblastic Leukemia

Interventions

  • FT819Drug

    Experimental Interventional Therapy

  • CyclophosphamideDrug

    Lympho-conditioning agent

  • FludarabineDrug

    Lympho-conditioning agent

  • IL-2Drug

    Biologic response modifier

  • BendamustineDrug

    Lympho-conditioning agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and nature of dose-limiting toxicities within each dose level cohortTime frame: Up to Day 29
  2. Incidence, nature, and severity of adverse events (AEs) of FT819 as monotherapy and in combination with IL-2 in r/r B-cell lymphoma, r/r chronic lymphocytic leukemia, and r/r precursor B-cell acute lymphoblastic leukemiaTime frame: Up to 15 years

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Arizona

    Phoenix, Arizona

  • UC Davis

    Davis, California

  • Scripps Green Hospital

    La Jolla, California

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California

  • Stanford Cancer Institute

    Palo Alto, California

  • University of Florida

    Gainesville, Florida

  • Mayo Florida

    Jacksonville, Florida

  • University of Iowa

    Iowa City, Iowa

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Norton Cancer Institute, St. Matthews Campus

    Louisville, Kentucky

  • Mayo Minnesota

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Oregon Health & Sciences University

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Wisconsin-Madison

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.